ATRX and central nervous system cancer: Given H3.3/ATRX co-localize with PML (Fig. 1A), and PML-NBs are a known oncogenic driver in acute promyelocytic leukemia, we asked if the H3.3/ATRX mutations might be affecting the PML pathway in pediatric gliomas.